Drug Trial Radar · NCT04204057
Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Last checked: Nov 19, 2026Latest source record: Aug 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
21
Actual
Start
Nov 28, 2019
Primary completion
Oct 2, 2020
Study completion Oct 2, 2020
Sponsor
- Lead sponsor
- Rhizen Pharmaceuticals SAIndustry
- Sponsor type
- Industry
- First posted
- Dec 18, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The trial is a Phase II, open label, Simon's two stage study design to evaluate the efficacy and safety of Tenalisib in patients with CLL who have relapsed or are refractory after at least one prior therapy.
Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
TenalisibDrug
Tenalisib 800 mg BID, Orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR)Time frame: 7 Months
- Duration of Response (DoR)Time frame: 7 Months
Locations
6 sites in 3 countries. Site status is shown where the registry gives one.
University Multiprofile Hospital for Active Treatment "Dr Georgi Stranski" Ltd.,
Pleven, Bulgaria
University Multiprofile Hospital for Active Treatment "Sv Ivan Rilski" Ltd
Sofia, Bulgaria
Ltd. M.Zodelava Hematology Centre
Tbilisi, Georgia
Medivest - Institute of Hematology and Transfusiology
Tbilisi, Georgia
Silesian Healthy Blood Clinic Grosicki, Grosicka Sp.J.
Chorzów, Poland
Voivodship Multi-Specialist Center for Oncology and Traumatology M. Copernicus
Lodz, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.